

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the “Announcement in Relation to the Acceptance of a Subsidiary’s Drug Registration Application” published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Yuqing

Chairman

Shanghai, the PRC

5 February 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* for identification purposes only

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Announcement in Relation to the Acceptance of a Subsidiary's Drug Registration Application

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, the drug registration application of 复迈宁® (generic name: Luvometinib Tablets; the “**Drug**”) self-developed by Shanghai Fosun Pharmaceutical Industrial Development Company Limited* (上海復星醫藥產業發展有限公司), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司) (the “**Company**”) for the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection (the “**Additional Indication**”), has been accepted by the National Medical Products Administration (“**NMPA**”) and included in the List of Priority Review.

II. Basic Information and Research Progress of the Drug

The Drug is an innovative small molecule chemical drug self-developed by the Group (i.e., the Company and its subsidiaries/units, the same applies below), which is a MEK1/2 selective inhibitor.

As at the date of this announcement (i.e., 5 February 2026), the other regulatory or clinical progress of the Drug is as follows:

1. The Drug has already been approved for marketing in China¹ with two approved indications, including (1) the treatment of adult patients with Langerhans cell histiocytosis

¹ excluding Hong Kong, Macau and Taiwan for the purpose of this announcement, the same applies below

(LCH) and histiocytic neoplasms; (2) the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.

2. The Drug for the treatment of pediatric patients aged 2 years and older with Langerhans cell histiocytosis (LCH) has been accepted by the NMPA and included in the List of Priority Review.

3. The Drug is at the stage of Phase III clinical trial in China for the treatment of children with low-grade glioma. The Drug is at the stage of Phase II clinical trial in China for the treatment of extracranial arteriovenous malformations.

As of December 2025, the Group had invested approximately RMB663 million (unaudited) in total in the research and development (the “R&D”) of the Drug at this stage.

According to the latest data from IQVIA MIDAS^{TM2}, the sales of MEK1/2 selective inhibitor worldwide amounted to approximately US\$2,068 million in 2024.

III. Risk Warning

The Additional Indication is subject to, among others, the drug registration approval before commercialization. This acceptance of the drug registration application will not have a material impact on the results of the Group at this stage.

Due to the industry characteristics of the pharmaceutical products, the specific sales performance after the market launch of pharmaceutical products may be affected by factors including, but not limited to, the demand for medication, market competition and sales channels, etc., and is subject to considerable uncertainty. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

5 February 2026

* *For identification purposes only*

² Data provided by IQVIA, a provider of professional medical and health information and strategic consultation service in the world.